MedTrace Logo

Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH)

NCT02323685 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2016-10-27

No results posted yet for this study

Summary

Safety and effect of SANGUINATE on patients DCI following SAH.

Conditions

  • Cerebral Ischemia

Interventions

BIOLOGICAL

SANGUINATE™

Single infusion of SANGUINATE (pegylated carboxyhemogloblin)

Sponsors & Collaborators

  • Prolong Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Michael N Dirringer, MD · Barnes Jewish Hospital/Washington University

  • Rajat Dhar, MD · Barnes Jewish Hospital/Washington University

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2016-06-30
Completion
2016-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02323685 on ClinicalTrials.gov